Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VRAYLAR vs ABILIFY MAINTENA KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Schizophrenia,Acute treatment of manic or mixed episodes associated with bipolar I disorder,Depressive episodes associated with bipolar I disorder (bipolar depression)
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
The terminal elimination half-life of cariprazine is 2-4 days, and for its active metabolites (desmethylcariprazine and didesmethylcariprazine) it is 1-3 weeks. This long half-life results in steady-state concentrations being reached after 3-4 weeks of daily dosing, contributing to prolonged clinical effects and a need for slow titration.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6. Active metabolites include didesmethylcariprazine (DDCAR) and desmethylcariprazine (DCAR).
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Cariprazine and its active metabolites are primarily eliminated via hepatic metabolism and subsequent biliary/fecal excretion. Approximately 20% of the dose is recovered in urine, mainly as inactive metabolites, while about 80% is recovered in feces, largely as unchanged cariprazine and its active metabolites.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Cariprazine is 91-97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution (Vd/F) is approximately 8.3 L/kg, indicating extensive tissue distribution and high lipophilicity.
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Absolute oral bioavailability is not determined; however, after oral administration, peak plasma concentrations occur within 3-6 hours. Food does not significantly affect the extent of absorption.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1.5 mg daily; maximum 3 mg/day. Child-Pugh Class C: Not recommended.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Safety and efficacy not established in pediatric patients under 18 years; not recommended.
Not approved for pediatric use.
Elderly patients may have lower clearance; use lowest effective dose (1.5 mg daily) and titrate slowly. Not approved for dementia-related psychosis due to increased mortality risk.
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse reactions in elderly patients with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Leukopenia, neutropenia, and agranulocytosis,Orthostatic hypotension and syncope,Falls,Seizures,Body temperature dysregulation,Dysphagia,Cognitive and motor impairment
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Known hypersensitivity to cariprazine or any components of the formulation
Hypersensitivity to aripiprazole or any excipients in the formulation.
No specific food restrictions. Vraylar can be taken with or without food. Grapefruit and grapefruit juice do not significantly interact with Vraylar. High-fat meals do not affect absorption.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following late third trimester exposure. Vraylar (cariprazine) is classified as Pregnancy Category C; no adequate human studies.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
Excretion into human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, discontinue drug or nursing, considering importance of drug to mother.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
No established dosing adjustments for pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure. Use lowest effective dose and monitor clinical response and tolerability. Clinical pharmacokinetic data not available; consider empiric dose adjustment based on tolerability.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Vraylar (cariprazine) requires dose adjustment in moderate hepatic impairment (Child-Pugh B): maximum dose 3 mg/day. Avoid in severe hepatic impairment (Child-Pugh C). Titrate slowly to minimize akathisia risk. For acute mania, start at 1.5 mg/day on day 1, increase to 3 mg/day on day 2. For schizophrenia, start at 1.5 mg/day, may increase to 3 mg/day after 2 days, then further in 1.5 mg increments weekly. For bipolar depression, target dose is 1.5-3 mg/day; start at 1.5 mg/day, increase to 3 mg/day after 2 days if needed. Monitor for extrapyramidal symptoms, especially akathisia which is dose-dependent. Renal impairment: no dose adjustment needed. CYP3A4 inducers (e.g., rifampin) decrease exposure; may need dose increase. CYP3A4 inhibitors (e.g., ketoconazole) increase exposure; reduce dose.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Take Vraylar once daily with or without food. Swallow capsules whole; do not crush or chew.,Do not abruptly stop taking Vraylar without talking to your doctor; sudden discontinuation may cause withdrawal symptoms such as nausea, vomiting, or trouble sleeping.,Avoid alcohol and illicit drugs while taking Vraylar, as they can worsen side effects like dizziness or drowsiness.,You may experience restlessness or an urge to move (akathisia), especially during dose increases; tell your doctor if this occurs.,Vraylar may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how the medication affects you.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double up.,Contact your doctor immediately if you experience uncontrolled muscle movements, especially of the face or tongue, or signs of neuroleptic malignant syndrome (fever, muscle rigidity, confusion).,Store at room temperature 20-25°C (68-77°F), away from moisture and heat.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VRAYLAR vs ABILIFY MAINTENA KIT, answered by our medical review team.
VRAYLAR is a Atypical Antipsychotic that works by Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.. ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VRAYLAR and ABILIFY MAINTENA KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VRAYLAR is: 1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.. The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VRAYLAR and ABILIFY MAINTENA KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VRAYLAR is classified as Category C. First trimester: Limited data; based on animal studies, may cause fetal harm. Second and third trimesters: Risk of extrapyramidal and/or withdrawal symptoms in neonates following l. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.